Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
1.400
-0.015 (-1.06%)
At close: Oct 30, 2026, 4:00 PM EDT
1.420
+0.020 (1.43%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Pulmatrix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
5.11M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 7.81M | 508.00K | 6.96% |
| Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
| Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
| Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
| Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
| Dec 31, 2019 | 7.91M | 7.76M | 5,069.93% |
| Dec 31, 2018 | 153.00K | -182.00K | -54.33% |
| Dec 31, 2017 | 335.00K | -500.00K | -59.88% |
| Dec 31, 2016 | 835.00K | -366.00K | -30.47% |
| Dec 31, 2015 | 1.20M | 849.00K | 241.19% |
| Dec 31, 2014 | 352.00K | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Longeveron | 1.19M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 95.00K |
| Senti Biosciences Holdings | 55.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Azitra | 7.50K |
| Alaunos Therapeutics | 3.00K |
PULM News
- 2 days ago - Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study - GlobeNewsWire
- 6 days ago - Pulmatrix Transcript: EGM 2026 - Transcripts
- 10 days ago - Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse - GlobeNewsWire
- 25 days ago - Pulmatrix Proxy statement: Proxy filing - Filings
- 27 days ago - Pulmatrix Registration statement: Registration filing - Filings
- 5 weeks ago - Pulmatrix Proxy statement: Proxy filing - Filings
- 5 weeks ago - Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria - GlobeNewsWire
- 2 months ago - Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger - PRNewsWire